Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Neoplasms 1Lung Neoplasms 1Lung Diseases 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1

Interventions

Carboplatin 9Pemetrexed 7osimertinib 5pembrolizumab 3entinostat 3durvalumab 3Radiosurgery 3Cisplatin 3Bevacizumab 3selpercatinib 2camrelizumab 2Paclitaxel 2Gemcitabine 2Erlotinib Hydrochloride 2Docetaxel 2trametinib 1sotorasib 1repotrectinib 1pralsetinib 1patritumab 1nazartinib 1napabucasin 1icotinib 1exemestane 1cobimetinib 1ceralasertib 1cemiplimab 1capmatinib 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchial Neoplasms × TNFSF10 protein, human × Thoracic × Clear all
NCT03083743 2017-03-20

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Shanghai Gebaide Biotechnology Co., Ltd.

Phase 3 Unknown
417 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡